Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road Manchester, M20 4BX, UK.
Future Oncol. 2019 Jul;15(20):2327-2335. doi: 10.2217/fon-2018-0067. Epub 2019 Jul 15.
Breast cancer remains a leading cause of death worldwide. Our increased understanding of cellular mechanisms inherent to cancer has led to the development of new therapeutic targets. One such therapy is that of poly(ADP-ribose) polymerase (PARP) inhibitors, with PARP playing a key role in the repair of single stranded DNA breaks. The development of drugs able to inhibit PARP led to their investigation in tumors that have defective DNA repair, including that of -associated cancers. The PARP inhibitor Olaparib, has recently been evaluated in the Phase III OlympiAD trial, and demonstrated a significant progression-free survival advantage in patients with HER2-negative metastatic breast cancer and a germline BRCA-mutation. This article will review the findings and potential implications of the trial.
乳腺癌仍然是全球范围内主要的死亡原因。我们对癌症内在细胞机制的理解不断加深，这导致了新的治疗靶点的发展。其中一种治疗方法是聚（ADP-核糖）聚合酶（PARP）抑制剂，PARP 在修复单链 DNA 断裂中起着关键作用。能够抑制 PARP 的药物的开发导致了它们在具有缺陷 DNA 修复的肿瘤中的研究，包括与 BRCA 相关的癌症。PARP 抑制剂奥拉帕利（Olaparib）最近在 III 期 OlympiAD 试验中进行了评估，并且在 HER2 阴性转移性乳腺癌和种系 BRCA 突变的患者中显示出显著的无进展生存期优势。本文将回顾该试验的结果和潜在影响。
